Key Points
- Deborah Ann Miller sold 5,500 shares on April 30 at an average price of $99.22 for $545,710, leaving her with 59,634 shares (an 8.44% reduction in her holdings).
- Analysts are mostly positive with a consensus "Moderate Buy" and an average target of $137.25, though price targets range from about $116 to $155 and one firm (Weiss) maintains a sell rating.
- Institutional ownership is very high at 97.26%; shares trade near $99 (market cap ~$7.79B) and sit slightly below their 50‑ and 200‑day moving averages (~$101.9).
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 5,500 shares of the company's stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $99.22, for a total transaction of $545,710.00. Following the sale, the insider owned 59,634 shares in the company, valued at $5,916,885.48. This represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Nuvalent Trading Down 1.2%
Shares of NASDAQ NUVL opened at $99.04 on Friday. The firm's 50-day moving average price is $101.94 and its 200-day moving average price is $101.89. The stock has a market capitalization of $7.79 billion, a price-to-earnings ratio of -16.93 and a beta of 1.15. Nuvalent, Inc. has a 12-month low of $63.56 and a 12-month high of $113.01.
Analysts Set New Price Targets
Several analysts have recently issued reports on NUVL shares. Wells Fargo & Company began coverage on shares of Nuvalent in a research report on Monday, March 30th. They set an "overweight" rating and a $116.00 target price on the stock. Wedbush reissued an "outperform" rating and issued a $125.00 price objective on shares of Nuvalent in a research report on Wednesday, April 8th. Cantor Fitzgerald increased their price objective on shares of Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Friday, February 27th. HC Wainwright reissued a "buy" rating and issued a $155.00 price objective on shares of Nuvalent in a research report on Tuesday, April 21st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Nuvalent in a research report on Tuesday, April 21st. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Nuvalent has a consensus rating of "Moderate Buy" and an average target price of $137.25.
Read Our Latest Research Report on Nuvalent
Institutional Trading of Nuvalent
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company's stock worth $34,000 after purchasing an additional 108 shares during the period. Kennedy Capital Management LLC grew its stake in Nuvalent by 1.5% in the 4th quarter. Kennedy Capital Management LLC now owns 10,932 shares of the company's stock worth $1,100,000 after acquiring an additional 163 shares in the last quarter. US Bancorp DE grew its stake in Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company's stock worth $179,000 after acquiring an additional 188 shares in the last quarter. Arizona State Retirement System grew its stake in Nuvalent by 1.9% in the 3rd quarter. Arizona State Retirement System now owns 11,778 shares of the company's stock worth $1,019,000 after acquiring an additional 220 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in Nuvalent by 7.7% in the 3rd quarter. Principal Financial Group Inc. now owns 3,290 shares of the company's stock worth $285,000 after acquiring an additional 234 shares in the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.
Nuvalent Company Profile
(
Get Free Report)
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
